Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation - Top-Institutions - MDSpire

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

  • By

  • Marco Salvini

  • Fabrizio Maggi

  • Camilla Damonte

  • Lorenzo Mortara

  • Antonino Bruno

  • Barbara Mora

  • Marco Brociner

  • Roberta Mattarucchi

  • Alessia Ingrassia

  • Davide Sirocchi

  • Benedetta Bianchi

  • Stefania Agnoli

  • Matteo Gallazzi

  • Michele Merli

  • Andrea Ferrario

  • Raffaella Bombelli

  • Daniela Barraco

  • Andreina Baj

  • Lorenza Bertù

  • Paolo A. Grossi

  • Francesco Passamonti

  • October 11, 2021

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology
    • Infectious Diseases

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Immunology
    • Infectious Diseases

Original Source(s)

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

  • by Marco Salvini, Fabrizio Maggi, Camilla Damonte, Lorenzo Mortara, Antonino Bruno, Barbara Mora, Marco Brociner, Roberta Mattarucchi, Alessia Ingrassia, Davide Sirocchi, Benedetta Bianchi, Stefania Agnoli, Matteo Gallazzi, Michele Merli, Andrea Ferrario, Raffaella Bombelli, Daniela Barraco, Andreina Baj, Lorenza Bertù, Paolo A. Grossi, Francesco Passamonti

  • October 11, 2021

Related Content

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders